Abstract library

20 results for "Custódio".
#368 The Role of Image and Chromogranin A Level at Diagnosis: A Portuguese Review of 19 Patients
Introduction: Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms. Biochemical neuroendocrine markers offer high sensitivity in establishing the diagnosis and, if correlated with image assessment, can provide important prognostic information.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Pedro Barata
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#950 Outcome of Malignant Insulinomas (MI) in the Community Setting
Introduction: MI is a rare and difficult to handle functional pancreatic neuroendocrine tumor with a variety of therapeutic alternatives.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: MD Carlos Lopez Lopez
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
#1196 CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)
Introduction: EVE is an mTOR inhibitor (mTORi) approved for the treatment of advanced pNETs. BEZ235, a dual mTOR/PI3K inhibitor, may provide greater PI3K pathway inhibition and enhanced antitumor effects.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Steven Libutti
Keywords: pNET, BEZ235, everolimus
#1213 Everolimus (EVE)-Induced Hyperglycemia (HG) in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs): Clinical Relevance and Predictive Value
Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
#1215 Describing NENs: Just Clinical/Biologic Features or Actual Prognostic Factors?
Introduction: Neuroendocrine neoplasias (NENs) are a rare group of diseases, with several possible locations and manifestations, often representing a challenging diagnosis. It is essential to improve tools that accurately predict aggressiveness and prognosis.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MSc Catarina Ribeiro
Authors: Ribeiro C, Gomes F, Semedo M, Filipe F, ...
#1316 Validation of Lysyl Oxidase-Like 2 (LOXL2) as Prognostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) Using an Independent Cohort.
Introduction: LOXL2 is a key protein to epithelial to mesenchymal transition. We showed LOXL2 has a role as a prognostic marker in 115 GEP-NET cases (training cohort (TC)).
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Jorge Barriuso
Keywords: LOXL2
#1389 Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain
Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms
Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.